| |
|
|
|
|
|
|
|||
|
Blood, 7 May 2009, Vol. 113, No. 19, pp. 4810-4818. Prepublished online as a Blood First Edition Paper on February 9, 2009; DOI 10.1182/blood-2008-07-170316.
Submitted July 23, 2008
Department of Vascular Biology, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Japan * Corresponding author; email: y-sato{at}idac.tohoku.ac.jp.
We recently isolated a novel angiogenesis inhibitor, vasohibin-1 and its homologue vasohibin-2. In this study we characterize the role of these 2 molecules in the regulation of angiogenesis. In a mouse model of subcutaneous angiogenesis, the expression of endogenous vasohibin-1 was low in proliferating ECs at the sprouting front, but high in non-proliferating ECs in the termination zone. In contrast, endogenous vasohibin-2 was preferentially expressed in mononuclear cells mobilized from bone marrow that infiltrated the sprouting front. When applied exogenously, vasohibin-1 inhibited angiogenesis at the sprouting front where endogenous vasohibin-1 was scarce, but did not influence vascularity in the termination zone where endogenous vasohibin-1 was enriched. Exogenous vasohibin-2 prevented the termination of angiogenesis in the termination zone and increased vascularity in this region. Angiogenesis was persistent in the termination zone in the vasohibin-1 knockout mice, whereas angiogenesis was deficient at the sprouting front in the vasohibin-2 knockout mice. Supplementation of deficient proteins normalized the abnormal patterns of angiogenesis in the vasohibin knockout mice. These results indicate that vasohibin-1 is expressed in ECs in the termination zone to halt angiogenesis, whereas vasohibin-2 is expressed in infiltrating MNCs in the sprouting front to promote angiogenesis.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2009 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||